Formulating the future

With the need for stress, anxiety, depression related healthcare products on the rise, Central Nervous System (CNS) disorders have become a strategically important therapeutic segment for Unichem.

The company’s CNS products seek to meet the needs of patients, neurologists, neurosurgeons and psychiatrists through a novel therapeutic approach.

Unichem has aggressively expanded and strengthened its position in this segment, covering a wide array of products that include anti-depressants, anti-psychotics, anxiolytics, cerebral activators, anti-platelets and neuropathic pain drugs. Unichem is eyeing many more new launches in this segment to consolidate its rank and position.

Unichem Laboratories Ltd., completes the sale and transfer of the Company’s domestic formulations business in India and Nepal to Torrent Pharmaceuticals Limited